Day: March 13, 2024

COLUMBUS, Ohio, March 13, 2024 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions, provided a performance update. The following tables present the Company’s net loss rate and delinquency rate for the periods indicated.  For themonth endedFebruary 29, 2024   For themonth endedFebruary 28, 2023  (dollars in millions)End-of-period credit card and other loans $ 18,391     $ 18,113  Average credit card and other loans(1) $ 18,541     $ 19,809  Year-over-year change in average credit card and other loans   (6 %)     20 %Net principal losses(1)(2) $ 131     $ 128  Net loss rate(1)(2)   8.9 %     7.8 %  As ofFebruary 29, 2024   As ofFebruary 28, 2023  (dollars in millions)30 days...

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy (DMD) patients whose mutations are amenable to an exon 51 skipping approach. PepGen is evaluating PGN-EDO51 for the treatment of DMD in the ongoing CONNECT1 Phase 2 trial, and expects to begin enrolling patients in the CONNECT2 Phase 2 trial later this year. “Receiving these FDA designations for PGN-EDO51 emphasizes the critical demand for novel and enhanced therapeutic...

— PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis — — Designation supported by encouraging preliminary data from 72-patient Phase 1 study — — 52-Week Data Accepted for Presentation at OARSI 2024 and 104-week data to be submitted for presentation later this year — TAMPA, Fla., March 13, 2024 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 (enekinragene inzadenovec), the company’s novel, intra-articular helper-dependent adenovirus (HDAd) gene therapy product candidate that codes for interleukin-1...

LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases. He most recently served as Vice President, Head of Neuromuscular Development Unit at Biogen, Inc. “Voyager is advancing rapidly toward the clinic, with one IND filing targeted each year through 2026 for our wholly-owned programs,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Toby brings an exceptional...

ST. LOUIS and CHICAGO, March 13, 2024 (GLOBE NEWSWIRE) — MX Holdings, a global leader in the purchasing, processing, and manufacturing of non-ferrous metals, together with Century Aluminum Company (NASDAQ: CENX) (“Century”), a global producer of primary aluminum, have entered a Memorandum of Understanding to establish a new joint venture focusing on the manufacture and marketing of low-carbon secondary billet. This new organization will deliver expertly engineered and technically advanced alloys, composed of increasingly high levels of recycled content produced with low-carbon processes. “We are excited to embark on this endeavor with Century – a partner whose business strategy and expertise complement our own and whose team shares our values and people-centric culture. By pairing our collective focus on customer service with a...

Enjoy Moments of Chill with Non-Alcoholic Mollo ‘Seltzers’ TORONTO, March 13, 2024 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced the expansion of its market-leading cannabis beverage portfolio with the latest release by its MOLLO® brand, introducing a lineup of new cannabis-infused non-alcoholic seltzers featuring the qualities of high cannabigerol (“CBG”) minor cannabinoid content, reminiscent of consumer favourite go-to low ABV beverages. Last year, Mollo launched a few new additions to its original lineup of refreshing non-alcoholic lagers including Mollo 5 and Mollo 101 beverages, along with its new fan favourite non-alcoholic cannabis-infused apple cider beverage, ORCHARD CHILL’R™, featuring a balance...

Fourth Quarter HighlightsCanadian Cannabis Delivers 14% Year-Over-Year Sales Increase, Positive Adjusted EBITDA and Cash Flow Canadian Cannabis Reclaims #2 National Market Share Position1 U.S. Cannabis Delivers Positive Adjusted EBITDA and Cash Flow Fresh Produce Delivers Significant Year-over-Year Improvement, With Positive Adjusted EBITDA for the YearAnnual HighlightsConsolidated Net Loss Per Share Narrows to ($0.29), Adjusted EBITDA Improves Significantly to $7.6 Million; Cash Flow from Operations Improves Significantly to $5.3 Million Canadian Cannabis Delivers 20-Fold Increase in Net Income and 10-Fold Increase in Adjusted EBITDA All Core Businesses Generate Positive Adjusted EBITDAVANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ:...

Partnership targets heart failure, the leading cause of death and a condition with limited treatment options BioCardia’s biotherapeutic delivery system with established safety profile enables minimally invasive transplantation of StemCardia’s off-the-shelf cardiac muscle cellsSUNNYVALE, Calif., March 13, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, and StemCardia, Inc., a biotechnology company focused on cell and gene therapy to re-muscularize the failing heart, today announced a long-term partnership to advance StemCardia’s investigational pluripotent stem cell product candidate for the treatment of heart failure. Under the partnership, BioCardia is the exclusive biotherapeutic delivery partner for StemCardia’s...

An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025Sol-Gel maintains a cash runway into the second half of 2025NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel, 2%), an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome and partnered with Galderma to commercialize two approved large-category dermatology products, TWYNEO® and EPSOLAY®, in the U.S, today announced financial results for the full year ended December 31st,...

ROBIT PLC        STOCK EXCHANGE RELEASE         13 MARCH 2024 AT 13.00 EET                      ROBIT PLC’S ANNUAL REPORT 2023 PUBLISHED Robit Plc’s Annual Report, Corporate Governance Statement and Remuneration Report for the year 2023 have today been published in Finnish and English on the company’s website at  https://www.robitgroup.com/investor/financial-information/.  The Annual Report contains Report of the Board of Directors and the Financial Statements 2023. The Financial Statements includes Consolidated Financial Statements, Robit Plc’s Parent Company’s Statements, and the Auditor’s Report. Robit Plc’s updated Remuneration Policy has also been published today on the aforementioned website. The pdf file of the Annual Report, Corporate Governance Statement, Remuneration Report and Remuneration Policy for the year 2023 are attached...